Founded out of Université catholique de Louvain and Wageningen University research, A-Mansia Biotech hopes to commercialise nutritional supplements for patients at heightened cardio-metabolic risk.

Oxford University Innovation expects to form 10 spinouts each year from an initiative for impact-led businesses.

Johnson & Johnson and AstraZeneca will get a chance to exit the orphan disease therapy developer, which has filed for an $86.3m IPO.

DSM Venturing co-led a $22.5m round for Miach Orthopaedics, which is developing an implant to treat ACL injuries.

PSL Innovation Fund has backed Gleamer, an automated radiology image analysis platform co-founded by a former École normale supérieure research student.

University of Manchester’s UMI3 has joined Frontier IP and Ingenza as a shareholder in newly-founded Plymouth antibiotics spinout Amprologix.

Stanford-StartX Fund-backed microbial diagnostics and wellness product developer UBiome has raised $83m in series C funding.

Microbial diagnostics and wellness product developer uBiome has received series C funding in a Dentsu Ventures-backed round.

Multi-university TTO Satt Sud-Est has licensed patents to GenOmnis for an RNA-based bioinformatics technology that will assess the pathogenicity of biological organisms.

Principia Biopharma, whose drug discovery platform is based on research at UCSF, has completed a $122m initial public offering after underwriters exercised their greenshoe option.